Administrative bulletin: 2026-07-004 Pharmacy updates
Date: July 1, 2026
Effective date: July 1, 2026
Topics covered in this administrative bulletin are applicable to:
Professional and facility Providers
Professional and facility Providers
Capital Blue Cross formulary update – Dapagliflozin replaces Farxiga
- CHIP
- EPO
- FEP PPO
- HMO
- Medicare Advantage HMO
- POS
- PPO
- Traditional and Comprehensive
- Medicare Advantage PPO
KEY POINT: Effective July 1, 2026, Farxiga has been removed, and the alternative, dapagliflozin has been added to the Capital Blue Cross Elite and Exclusive, Advantage, and Value Plus Formularies.
The following update reflects a change to previously published information regarding Capital’s July formulary updates. For the complete list, please refer to the May 2026 publication, Administrative bulletin 2026-05-004 Pharmacy updates.
Capital Blue Cross Formulary updateKEY: (PA) = Prior Authorization; (ST) = Step therapy; (QLL) = Quantity Level Limits lowercase bold print = generic; UPPERCASE PRINT = BRAND Formulary Status: Generic Preferred (GP), Generic Non-Preferred (GNP), Brand Preferred (BP), Brand Non-Preferred (BNP), Nonformulary (NF) |
|||
|---|---|---|---|
Removed from formulary effective July 1, 2026 |
|||
|
Brand name |
Tier status |
Indication |
Preferred alternative |
|
FARXIGA |
BP |
Antidiabetes |
dapagliflozin (ST, QLL) |